BEIJING, Sept. 4,
2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc.
(Nasdaq: CASI) ("CASI" or the "Company"), a Cayman incorporated
biopharmaceutical company specializing in the development and
commercialization of innovative therapeutics and pharmaceutical
products, today announced its participation in the H.C. Wainwright
26th Annual Global Investment Conference taking place
September 9-11, 2024, at the Lotte
New York Palace in New York City.
Members of the CASI management team, including Chief Financial
Officer Daniel Lang, MD, and Chief
Medical Officer Alexander Zukiwski,
MD, will host 1x1 investor meetings at the conference.
A pre-recorded corporate presentation will be available for
conference participants to view in "Virtual Room 1" at 7 a.m. Eastern Time on September 9th. Thereafter, the presentation will
be available on the Investors page of the CASI corporate website at
https://casipharmaceuticals.com/investor.html.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a biopharmaceutical company
focused on developing and commercializing innovative therapeutics
and pharmaceutical products in China, the United
States, and throughout the world. The Company is focused on
acquiring, developing, and commercializing products that augment
its focus on hematology oncology therapeutics and therapeutics for
organ transplant rejection and autoimmune disease, as well as other
areas of unmet medical need. The Company intends to execute its
plan to become a leader by launching medicines in the Greater China market, leveraging the Company's
China-based regulatory and
commercial competencies and its global drug development expertise.
The Company's operations in China
are conducted through its wholly owned subsidiary, CASI
Pharmaceuticals (China) Co., Ltd.,
located in Beijing, China. More
information on CASI is available at
www.casipharmaceuticals.com.
COMPANY CONTACT:
Rui Zhang
CASI Pharmaceuticals, Inc.
240.864.2643
ir@casipharmaceuticals.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/casi-pharmaceuticals-to-participate-in-the-2024-hc-wainwright-global-investment-conference-302237656.html
SOURCE CASI Pharmaceuticals
